Results from the AUGUSTUS trial show that atrial fibrillation (AF) patients with recent acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI) who receive a P2Y12 inhibitor experience less bleeding and fewer hospitalisations without significant differences in ischaemic events with an antithrombotic regimen that includes apixaban, without aspirin, than with regimens that include a vitamin K antagonist (VKA), aspirin, or both .
AUGUSTUS is an international, multicentre, randomised trial with a 2x2 factorial design to compare apixaban + aspirin or placebo with a VKA + aspirin or placebo in patients with AF who develop ACS and/or undergo PCI and are receiving a P2Y12 inhibitor. As such, it is the largest and only prospective randomised trial to investigate efficacy and safety of aspirin vs placebo with either non-VKA or VKA oral anticoagulation and a P2Y12 inhibitor for all patients.
Primary outcome of the study was the composi...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Superior outcomes of DES compared with BMS in very elderly population Next Article
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease »
Table of Contents: ACC 2019
Acute and Stable Ischaemic Heart Disease
Arrhythmias and Clinical Electrophysiology
Congenital Heart Disease
Heart Failure and Cardiomyopathies
Pulmonary Arterial Hypertension and Venous Thromboembolism
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.